TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31036879
Drug: Anti-GITR-based combination
Normalized name: Anti-gitr agonistic monoclonal antibody incagn01876
DrugBank: Ragifilimab (DB18853)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-GITR-based combination immunotherapy
Study: 31038469
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine 10 mg on visit 1
Study: 31038469
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 10 mg on visit 2
Study: 31038469
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine 30 mg on visit 3
Study: 31038469
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine 50 mg on visit 4
Study: 31038781
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with LDL-C below the target of 70 mg/dL
Study: 31038781
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who believe cholesterol treatment should be terminated when cholesterol normalizes
Study: 31039789
Drug: Severity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severity of insulin resistance (measured by HOMA-IR)
Study: 31039807
Drug: Intravenous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous abatacept (weight-tiered: <75 kg: 10 mg/kg; 75-100 kg: 750 mg; >100 kg: 1000 mg) administered at Weeks 0, 2, 4, and every 4 weeks thereafter for 16 weeks.
Study: 31040256
Drug: EGFR-TKI (erlotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR-TKI (erlotinib 150 mg or gefitinib 250 mg per day) plus thoracic radiotherapy (54-60 Gy/27-30 F/5.5-6 w)
Study: 31042669
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg subcutaneously twice-daily)
Study: 31042825
Drug: bb2121 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bb2121 CAR T-cell therapy
Study: 31043157
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration therapy (WBVT) - 20 Hz, 2 mm amplitude, 3 bouts of 3 minutes, 4 days per week for 4 weeks.
Study: 31043157
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration therapy (WBVT)
Study: 31043390
Drug: Low-dose vitamin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vitamin D (1,000 IU/day)
Study: 31043390
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D (5,000 IU/day)
Study: 31045222
Drug: Standard-dose intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intradermal influenza vaccine
Study: 31046714
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg q3w i.v. for 2 cycles)
Study: 31046720
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity on Prescription (PAP) treatment including individual counseling, tailored PA recommendation, written prescription, and structured follow-up for 6 months
Study: 31046720
Drug: Physical Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Activity on Prescription (PAP) treatment
Study: 31046743
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every third week in combination with entinostat 5 mg orally once weekly.
Study: 31046839
Drug: Intratumoral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral treatment with BO-112
Study: 31046839
Drug: Intratumoral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral treatment with BO-112 plus systemic anti-CD137 and anti-PD-L1 mAbs
Study: 31048330
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg Q2W
Study: 31048330
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg Q2W, 240 mg Q2W, 360 mg once every 3 weeks
Study: 31048330
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg, 240 mg, 360 mg
Study: 31049885
Drug: Cannabidiol oral
Normalized name: cannabidiol Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol oral solution (5, 10, or 20 mg/kg single dose on day 1; 10 mg/kg, 20 mg/kg, or 40 mg/kg total daily dose for days 4-10)
Study: 31049885
Drug: Cannabidiol oral
Normalized name: cannabidiol Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol oral solution (40 mg/kg/day) with clobazam
Study: 31053102
Drug: Dietary information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary information and environmental factors (gestational age, mode of delivery, maternal/infant diet, exposure to antibiotics)
Study: 31053156
Drug: HO volume
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HO volume measured by low-dose whole body CT
Study: 31055613
Drug: anti-CD19 CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CD19 CAR-T cell therapy
Study: 31055613
Drug: replacement and
Normalized name: INVEST HORMONE THERAPY/REPLACEMENT ANDROGEN AND ANABOLIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: replacement and anticoagulant therapy
Study: 31057004
Drug: Good adherence
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good adherence (taking medications ≥90% of the time as prescribed)
Study: 31057004
Drug: No medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medications prescribed during follow-up
Study: 31057004
Drug: Taking ≥1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking ≥1 medications
Study: 31057807
Drug: Carepartner and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carepartner and Constraint-Induced Therapy (CARE-CITE) with structured carepartner involvement during 30-h CIMT
Study: 31057807
Drug: Constraint-Induced Movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Movement Therapy (CIMT) without structured carepartner involvement
Study: 31058782
Drug: Additional antibiotic
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional antibiotic courses
Study: 31060562
Drug: Omega-3 intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 intake < 1.7 g/day
Study: 31060567
Drug: AS03-adjuvanted H5N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H5N1 vaccine (2-dose vaccination schedule)
Study: 31060612
Drug: Carboplatin/paclitaxel (C + P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin/paclitaxel (C + P) chemotherapy followed by HPV16-E7 synthetic long peptide (E7LP) vaccination
Study: 31060612
Drug: Tri-therapy: C + P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-therapy: C + P chemotherapy, E7LP vaccination, and intravaginal CpG
Study: 31060612
Drug: Nanoparticle-conjugated E7LP
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanoparticle-conjugated E7LP vaccine
Study: 31061035
Drug: Frequent binge
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent binge drinking between the age of 18 and 25 years (defined as more than twice a month)
Study: 31061070
Drug: Anti-PD-1 monotherapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 monotherapy
Study: 31061070
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of drugs targeting the IL17 signaling pathway with T-cell checkpoint inhibitors
Study: 31061681
Drug: Urinary TIMP2∗IGFBP7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary TIMP2∗IGFBP7 concentration > 2.0 (ng/ml)
Study: 31062633
Drug: Grape/pomegranate pomace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape/pomegranate pomace dietary supplement
Study: 31063537
Drug: cART based
Approvals — FDA: no, EMA: no, PMDA: no
Description: cART based on 2 nucleoside reverse transcriptase inhibitors plus 1 ritonavir-boosted protease inhibitor
Study: 31063862
Drug: Durvalumab, 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab, 1500 mg every 4 weeks, and Olaparib, 300 mg twice a day
Study: 31064851
Drug: SY-1365, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-1365, a selective CDK7 inhibitor
Study: 31065301
Drug: Probiotics added
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics added to antimicrobial treatment
Study: 31065624
Drug: Molecularly tailored
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly tailored therapy
Study: 31066879
Drug: Implementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation of prehospital TBI guidelines emphasizing avoidance/treatment of hypoxia, prevention/correction of hyperventilation, and avoidance/treatment of hypotension
Study: 31067538
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (PPI) treatment for 2 months
Study: 31067538
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of PPI treatment
Study: 31067570
Drug: Donor-derived HCMV-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor-derived HCMV-specific cytotoxic T cells (CTLs) as first-line therapy
Study: 31068222
Drug: Modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFIRINOX regimen (intravenous infusion of oxaliplatin, 65 mg/m2)
Study: 31068369
Drug: STM 434
Normalized name: STM 217
DrugBank: STM-217 (DB17358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: STM 434 (0.25 mg/kg every 4 weeks to 8 mg/kg every 2 weeks)
Study: 31072394
Drug: Future therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Future therapeutic HIV vaccine
Study: 31073292
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise as add-on treatment, details on dosage and duration not available
Study: 31074004
Drug: Tissue transglutaminase
Normalized name: Tissue transglutaminase IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue transglutaminase antibody levels
Study: 31075727
Drug: Dose-dense epirubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense epirubicin, paclitaxel and cyclophosphamide (EPC)
Study: 31075727
Drug: Dose-dense epirubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense epirubicin, cyclophosphamide, paclitaxel and capecitabine (EC-PwX)
Study: 31076409
Drug: Oral lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral lenalidomide 10 mg daily starting on day 9 of cycle 1 and IV rituximab 375 mg/m2
Study: 31076416
Drug: Prediabetes (IGT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediabetes (IGT or IFG) after revascularization, optimal medical therapy, or both
Study: 31077039
Drug: High-dose α-tocopherol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose α-tocopherol, N-acetylcysteine, and α-lipoic acid in combination
Study: 31077164
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with platinum-doublet chemotherapy
Study: 31077529
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (continuous subcutaneous insulin infusion for 7 days)
Study: 31079357
Drug: Teneligliptin 20
Normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Teneligliptin 20 mg qd for 12 weeks
Study: 31081020
Drug: 8-hourly lopinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-hourly lopinavir/ritonavir dosing strategy
Study: 31678203
Drug: Magnetically assisted
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetically assisted capsule endoscopy (MACE)
Study: 31082688
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitors (TKIs) with or without chemotherapy
Study: 31084325
Drug: Aspirin, Warfarin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, Warfarin, DOAC
Study: 31085605
Drug: iReadMore therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: iReadMore therapy (a therapy app for reading training)
Study: 31085763
Drug: Combination BRAF
Normalized name: Braftovi
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination BRAF and MEK inhibition
Study: 31085763
Drug: Cabozantinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib therapy
Study: 31086307
Drug: 160 L alglucosidase
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 160 L alglucosidase alfa
Study: 31087382
Drug: HBsAg vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg vaccine (Engerix-B) as challenge dose
Study: 31087457
Drug: Buccal bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal bone loss
Study: 31087772
Drug: Locoregional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapies (LRT)
Study: 31088809
Drug: Acalabrutinib 100
Normalized name: acalabrutinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 100 mg twice daily or 200 mg once daily
Study: 31088831
Drug: Erdafitinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdafitinib (oral pan-FGFR inhibitor)
Study: 31089278
Drug: Bu-Oral (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bu-Oral (oral busulfan)
Study: 31089278
Drug: Bu-IV (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bu-IV (intravenous busulfan)
Study: 31089689
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin A supplement (1.0 μmol [14,15]-13C2-retinyl acetate)
Study: 31089689
Drug: Routine 200,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine 200,000 IU vitamin A capsule administered after RID test
Study: 31089689
Drug: Receiving 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving 2 or 3 vitamin A supplements in the past 12 months
Study: 31090044
Drug: Sarilumab 150
Normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 150 mg subcutaneously every 2 weeks for 24 weeks
Study: 31090044
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg subcutaneously every 2 weeks for 24 weeks
Study: 31092022
Drug: AFEQT subscale
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFEQT subscale Activities of Daily Living
Study: 31095609
Drug: Hypoalbuminemia (P-Alb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoalbuminemia (P-Alb < 34g/L)
Study: 31095609
Drug: Normal albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal albumin levels (P-Alb ≥ 34g/L)
Study: 31096006
Drug: Direct-acting antiviral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antiviral (DAA) therapy with sustained virologic response (SVR)
Study: 31096937
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) at 1.5 g/kg/day, days 1-3, with mFOLFOX6 or FOLFIRI
Study: 31096937
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) at 0.2-1.5 g/kg, 3-h infusion, once daily, days 1-3, with mFOLFOX6 or FOLFIRI
Study: 31096944
Drug: Multifaceted community-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted community-based intervention including parent workshops on nutrition and physical activity, school-based nutrition lessons, enhanced physical education, and monthly vouchers for fruits and vegetables.
Study: 31096979
Drug: Dienogest (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienogest (2 mg/daily)
Study: 31097012
Drug: Fluid challenge
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid challenge (FC) of 500 mL crystalloids over 10 min
Study: 31097024
Drug: Intermittent nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nivolumab for 12 weeks; 5 patients (36%) met criteria for intermittent phase with a median tumor burden decrease of 46%; all agreed to intermittent therapy.
Study: 31097024
Drug: Intermittent nivolumab;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nivolumab; acceptance rate for intermittent therapy was 100% among those eligible (5 out of 5).
Study: 31097294
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (10 mg/70 kg)
Study: 31097487
Drug: Rotavirus vaccine
Normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotavirus vaccine introduction
Study: 31099252
Drug: AMD11070 (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMD11070 (an orally administered CXCR4 entry inhibitor)
Study: 31099895
Drug: CYP450 activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP450 activities assessed after a single oral administration of a cocktail of probe drugs
Study: 31100456
Drug: Remission-time equivalents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission-time equivalents (RTE) for symptom severity or treatment-related risk
Study: 31101422
Drug: emm75 GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: emm75 GAS doses applied by swab to the pharynx
Study: 31101422
Drug: Antibiotics treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics treatment for all participants
Study: 31101489
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin in combination with R-CHP (cyclophosphamide, doxorubicin, prednisone)
Study: 31101489
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin in combination with G-CHP (obinutuzumab, cyclophosphamide, doxorubicin, prednisone)
Study: 31101577
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 to 5 mg daily)
Study: 31102044
Drug: Full-mouth disinfection
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth disinfection (FMD) protocol including full-mouth scaling and root planing within 24 hours, application of chlorhexidine digluconate (CHX) gel in pockets and tongue plus CHX rinses for 14 days
Study: 31102143
Drug: Immuno-Oncology (IO)
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immuno-Oncology (IO) treatments
Study: 31102144
Drug: OnabotulinumtoxinA 155
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA 155 U administered every 12 weeks
Study: 31104505
Drug: No migraine-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: No migraine-specific rescue medication
Study: 31106898
Drug: Hydroxyurea, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea, single oral dose of 20 mg/kg, followed by PK-guided dosing
Study: 31106898
Drug: Hydroxyurea, PK-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea, PK-guided dosing
Study: 31106898
Drug: Traditional weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional weight-based dosing
Study: 31107260
Drug: Closed-loop (CL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop (CL) system for propofol administration with BIS target between 40 and 50
Study: 31107300
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitors
Study: 31107300
Drug: Integrase inhibitors
Normalized name: Integrase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrase inhibitors (yes or no)
Study: 31107869
Drug: Triple-drug therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug therapy (IVM + DEC + ALB)
Study: 31108163
Drug: Clinician-administered KSADS-COMP
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-administered KSADS-COMP
Study: 31108163
Drug: Youth self-administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Youth self-administered KSADS-COMP
Study: 31108163
Drug: Parent self-administered
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent self-administered KSADS-COMP
Study: 31108510
Drug: ITF-rich vegetables
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF-rich vegetables (15 g ITF/d)
Study: 31110648
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone 400 mg daily at bedtime from 28 weeks until delivery
Study: 31110648
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment other than normal tonics)
Study: 31111867
Drug: Salt intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt intake 1 g/d higher in Japan
Study: 31111867
Drug: Salt intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt intake 1 g/d higher in China
Study: 31111867
Drug: Salt intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt intake 1 g/d higher in the United Kingdom
Study: 31111867
Drug: Salt intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt intake 1 g/d higher in the United States
Study: 31112476
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy followed by N-AVD (doxorubicin, vinblastine, and dacarbazine)